Anebulo Pharmaceuticals, Inc. (ANEB) stock analysis
Close on Oct 19, 2026Market cap $28.76KP/E –Yield –
StockData Score
Prices as of Nov 13, 2026How the score works
Weak0 of 30 checks passed
Anebulo Pharmaceuticals passes 0 of the 30 checks behind our score; 26 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 0/6
- Past performance
- 0/6
- Financial health
- 0/6
- Dividend
- 0/6
What stands out
Anebulo Pharmaceuticals passes none of the checks.
What to watch
Return on equity under 15%
Return on equity was -69.7% over the last twelve months and averaged -127% over five years; we look for 15% on both.
Interest not well covered
Operating income covers interest expense -21.0 times; we look for at least 5.
Return on equity below the industry
Anebulo Pharmaceuticals's return on equity of -69.7% is below the Drugs median of -57.0%.
No dividend
Anebulo Pharmaceuticals has not paid a dividend in the last twelve months.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B against the industry
Needs positive book value.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth0/6
Revenue growth over 3 years
Needs three years of positive revenue.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growth against the industry
Needs revenue for this year and last.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin trend
This company does not report gross profit.
Past performance0/6
Return on equity under 15%
Return on equity was -69.7% over the last twelve months and averaged -127% over five years; we look for 15% on both.
Return on invested capital
Needs operating income and invested capital.
Return on equity below the industry
Anebulo Pharmaceuticals's return on equity of -69.7% is below the Drugs median of -57.0%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin against the industry
Needs revenue and net income.
Financial health0/6
Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt coverage
Needs operating cash flow.
Interest not well covered
Operating income covers interest expense -21.0 times; we look for at least 5.
Short-term liquidity
The balance sheet is not split into current and non-current items.
Bankruptcy risk (Altman Z)
Needs market value, working capital and retained earnings.
Dividend0/6
No dividend
Anebulo Pharmaceuticals has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Anebulo Pharmaceuticals. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/B at month end
- Own 5-year median 5.3
- Drugs median 2.1
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -109.7% | |
| Return on assets | – | – | -104.6% | |
| Interest coverage | – | – | -23.1× | |
| Diluted shares | – | – | 34M |
Cash use needs five years of cash flow figures
Anebulo Pharmaceuticals does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero-$8.48M
- Cash generatingOperating cash flow above zero-$6.35M
- Return on assets improvedROA up on the prior year-70.3% → -208.3%
- Earnings backed by cashOperating cash flow above net income-$6.35M vs -$8.48M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose– → –
- No dilutionShare count did not rise26M → 34M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –
See a number that looks wrong?